AXIM · Axim Biotechnologies, Inc. · Shareholders & Ownership
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the ability of the Company to continue as a going concern. The financial statements do not include any adjustments related to the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue in operation.”View the 10-Q filed Aug 19, 2024
Every disclosed holder of AXIM in one list: 13F institutions, Schedule 13D and 13G filers, insiders (Forms 3, 4 and 5) and registered funds, each from its own latest filing. Holders nest by CIK and SEC reporting links, never by name, and each is summed once.
Who Owns AXIM
13F quarter Dec 31, 2022| Holder group | Shares | % Out |
|---|---|---|
| Institutional (13F) | 500 | 0.00% |
| Insiders (Forms 3, 4, 5) | 0 | 0.00% |
| 13D/G-only blocks | 0 | 0.00% |
| Remaining | 301,958,324 | 100.00% |
| Registered funds (N-PORT, not summed) | 0 | 0.00% |
Shares outstanding: 301,958,824, the issuer's latest cover-page count restated onto today's split basis.
Insiders are listed but not summed: the issuer has more than one class of common stock and Forms 3, 4 and 5 report one issuer-wide balance across them.
13D/G-only counts each filer's latest 13D or 13G that no 13F report of the listing contains, that names no 13F filer and that no counted insider files. Funds are never summed: their shares sit inside their advisers' 13F reports.
Holders of AXIM
| # | Holder | Shares | As of | Notes |
|---|---|---|---|---|
| 1 |
MassMutual Private Wealth & Trust, FSB
13F
CIK 1103653 · Unknown · Dec 31, 2022
|
500 |
Shares are restated onto today's split basis. Change compares each row with the same holder's previous filing in the same source; a dash means there is none to compare. Nested 13D/G, insider and fund rows are not summed, since a 13F report already holds them.